Pandemic, Plandemic, or Both? (Part 2)

• When political correctness is put aside, SARS-CoV-2 is Covid-19's real name.
• The combined staff of the CDC and the NIH is, at last count, about 31,000.
• The American pharmaceutical company most engaged in the SARS-CoV-2 episode, Gilead Sciences, has a dodgy history, and is being sued by the U.S. Government for patent infringement.
• Gilead's drug, Remdesivir, being pushed hard by the federal government's medical establishment, is a failed effort left over from the search for a hepatitis C drug.

"While health officials stress that the likelihood of the novel coronavirus spreading in the U.S. and Washington is relatively low, anyone who has traveled from Wuhan, China should monitor their symptoms and contact their health care provider if they experience fever, cough or shortness of breath. Symptoms can present themselves in as few as two days or as long as two weeks after exposure, according to the CDC. Risk to the general public is still low, however."

Support Canada Free Press

Race to mass produce and distribute Remdesivir was well underway in China

Lutz: (9:18) "We were very ill prepared at the federal level, which, again, has really hampered us at the state level, and therefore at the local level to really proceed and to really address the pandemic in a way that we really could have and or should have."   Reporter: "…when did you really start reading about Covid-19 in other parts of the world and start to get concerned, and I'm curious if you started sounding alarms in our health district here and started preparing here, when did that thought process begin with you and started to affect your work?"   Lutz: (10:05) "The first awareness we had in the United States was soon, you know, late December – early January, and I think to Department of Health's credit, as you know, was it in in the media a week ago, a week and a half ago, they noted that they had essentially been monitoring Covid-19 for over 100 days. We did not have formal recognition of monitoring,  but with that said, anybody who was in public health following infectious disease, epidemiology, health officers, we were well aware of the fact that an epidemic which was certainly in the making in China was, without doubt, going to move to the United States. And as it did, we were quickly monitoring it. So I think, that to our credit, we actually did have an incident command structure, we had that incident command set up in, I wanna say, late January – early February, and we were meeting…and then, obviously, when the very first case developed in Washington State, that really raised everybody's awareness.  So, we saw it coming. We were very much concerned about it. Were we prepared? Internally, we had done enough preparation, we had plans in place…(11:35) But overall I would say that it's been challenging because the preparation, really not so much locally, and not so much at the state level, but preparedness was really not to the degree that it should have been."  

Labs in China compete to corner the Remdesivir market

"A publicly traded Chinese drug developer, BrightGene Bio-Medical Technology Co., said today it has successfully manufactured the active pharmaceutical ingredients (APIs) of remdesivir (GS-5734), the Gilead Science antiviral candidate being tested in China human clinical trials as a treatment for the 2019-nCoV novel coronavirus." "'[BrightGene] actively responded to the national call to fight the new coronavirus (2019-nCoV) epidemic, and recently successfully developed and synthesized the technology and preparations for the drug synthesis of [remdesivir] technology,' the company stated today." "'The company successfully imitated the development and production of [remdesivir] APIs by virtue of its technical accumulation in the development of high-end APIs and special injections,' BrightGene added in its statement, issued through the Shanghai Stock Exchange. 'The company has produced [remdesivir] bulk drugs, and the batch production of Remdesivir preparations is in progress.'" "BrightGene acknowledged that its marketing of remdesivir 'still needs to be authorized' by Gilead, adding, 'There are many uncertainties in this process, such as drug approval.' BrightGene did not discuss in its statement what if any efforts the company has undertaken to pursue authorization from Gilead for the imitation product: 'If the product can be approved for marketing, it will be supplied to relevant patients mainly through donations during the epidemic.'"

"Last week, researchers at China's Wuhan Institute of Technology applied for a Chinese patent for the use of Gilead Sciences antiviral candidate remdesivir as a treatment for coronavirus, potentially in combination with chloroquine."

Several China labs rushed to field-test Remdesivir

"The U.S. Centers for Disease Control and Prevention will be testing for the coronavirus in people in five major cities who show up at clinics with flu-like symptoms but who test negative for the seasonal varieties.  If that testing shows the virus has slipped into the country in places federal officials don't know about, 'we've got a problem,' Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told USA TODAY's Editorial Board Monday." "Short of that, Fauci says skip the masks unless you are contagious, don't worry about catching anything from Chinese products and certainly don't avoid Chinese people or restaurants…Fauci doesn't want people to worry about coronavirus, the danger of which is 'just minuscule.' But he does want them to take precautions against the 'influenza outbreak, which is having its second wave." "'We have more kids dying of flu this year at this time than in the last decade or more,' he said. 'At the same time people are worrying about going to a Chinese restaurant. The threat is (we have) a pretty bad influenza season, particularly dangerous for our children.'"

VIEW Comments